A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

• Age ≥18 years or country's legal age of majority if the legal age is >18 years old at the time of enrollment

• Patients with RRMM who have at least one prior line of therapy

• Patients for whom the treating physician has made the decision to initiate isatuximab per routine practice and independently of the purpose of the study; for retrospectively enrolled patients, exposure to isatuximab treatment for a maximum of three months prior to study enrollment

• Able to understand and complete the study-related questionnaires

• Patient must have given signed informed consent prior to study start. For retrospectively enrolled patients who are deceased at the date of enrollment into the study, a waiver of consent will be required; patients who have started and stopped treatment or whose treatment is still ongoing at ICF are eligible

Most important exclusion criteria for potential participants:

• Patients who are receiving isatuximab for an indication other than RRMM

• Patients who have received any other investigational drug or prohibited therapy for this study within 28 days or five half-lives from randomization, whichever is longer

• Patients having contraindication to the isatuximab summary of product characteristics (SMPC) or package insert (PI)

• Patients having contraindications as noted in the drug-specific local isatuximab SMPC/PI of combination drugs

• Any country-related specific regulation that would prevent the patient from entering the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. Further eligibility criteria might apply.